Cargando…

Prevalence, diagnosis, and treatment of primary hepatic gastrointestinal stromal tumors

Gastrointestinal stromal tumors (GIST), which is the most common mesenchymal tumor of the digestive tract, account for 1%-3% of gastrointestinal tumors. Primary stromal tumors outside the gastrointestinal tract are collectively referred to as extra GISTs, and stromal tumors in different regions ofte...

Descripción completa

Detalles Bibliográficos
Autores principales: Qian, Xiao-Hui, Yan, Ying-Cai, Gao, Bing-Qiang, Wang, Wei-Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7596635/
https://www.ncbi.nlm.nih.gov/pubmed/33177793
http://dx.doi.org/10.3748/wjg.v26.i40.6195
_version_ 1783602156793757696
author Qian, Xiao-Hui
Yan, Ying-Cai
Gao, Bing-Qiang
Wang, Wei-Lin
author_facet Qian, Xiao-Hui
Yan, Ying-Cai
Gao, Bing-Qiang
Wang, Wei-Lin
author_sort Qian, Xiao-Hui
collection PubMed
description Gastrointestinal stromal tumors (GIST), which is the most common mesenchymal tumor of the digestive tract, account for 1%-3% of gastrointestinal tumors. Primary stromal tumors outside the gastrointestinal tract are collectively referred to as extra GISTs, and stromal tumors in different regions often have different prognoses. A primary hepatic GIST is a rare tumor with an unknown origin, which may be related to interstitial Cajal-like cells. Although primary hepatic GIST has certain characteristics on imaging, it lacks specific symptoms and signs; thus, the final diagnosis depends on pathological and genetic evidence. This review summarizes all cases of primary hepatic GIST described in the literature and comprehensively analyzes the detailed clinical data of all patients. In terms of treatment, local resection alone or with adjuvant therapy was the prioritized choice to obtain better disease-free survival and longer survival time. For advanced unresectable cases, imatinib mesylate was applied as the first-line chemotherapy agent. Moreover, transcatheter arterial chemoembolization, radiofrequency ablation, and microwave ablation were shown to improve overall survival for selected patients. Liver transplantation was a final treatment option after resistance to chemotherapy developed.
format Online
Article
Text
id pubmed-7596635
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-75966352020-11-10 Prevalence, diagnosis, and treatment of primary hepatic gastrointestinal stromal tumors Qian, Xiao-Hui Yan, Ying-Cai Gao, Bing-Qiang Wang, Wei-Lin World J Gastroenterol Minireviews Gastrointestinal stromal tumors (GIST), which is the most common mesenchymal tumor of the digestive tract, account for 1%-3% of gastrointestinal tumors. Primary stromal tumors outside the gastrointestinal tract are collectively referred to as extra GISTs, and stromal tumors in different regions often have different prognoses. A primary hepatic GIST is a rare tumor with an unknown origin, which may be related to interstitial Cajal-like cells. Although primary hepatic GIST has certain characteristics on imaging, it lacks specific symptoms and signs; thus, the final diagnosis depends on pathological and genetic evidence. This review summarizes all cases of primary hepatic GIST described in the literature and comprehensively analyzes the detailed clinical data of all patients. In terms of treatment, local resection alone or with adjuvant therapy was the prioritized choice to obtain better disease-free survival and longer survival time. For advanced unresectable cases, imatinib mesylate was applied as the first-line chemotherapy agent. Moreover, transcatheter arterial chemoembolization, radiofrequency ablation, and microwave ablation were shown to improve overall survival for selected patients. Liver transplantation was a final treatment option after resistance to chemotherapy developed. Baishideng Publishing Group Inc 2020-10-28 2020-10-28 /pmc/articles/PMC7596635/ /pubmed/33177793 http://dx.doi.org/10.3748/wjg.v26.i40.6195 Text en ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
spellingShingle Minireviews
Qian, Xiao-Hui
Yan, Ying-Cai
Gao, Bing-Qiang
Wang, Wei-Lin
Prevalence, diagnosis, and treatment of primary hepatic gastrointestinal stromal tumors
title Prevalence, diagnosis, and treatment of primary hepatic gastrointestinal stromal tumors
title_full Prevalence, diagnosis, and treatment of primary hepatic gastrointestinal stromal tumors
title_fullStr Prevalence, diagnosis, and treatment of primary hepatic gastrointestinal stromal tumors
title_full_unstemmed Prevalence, diagnosis, and treatment of primary hepatic gastrointestinal stromal tumors
title_short Prevalence, diagnosis, and treatment of primary hepatic gastrointestinal stromal tumors
title_sort prevalence, diagnosis, and treatment of primary hepatic gastrointestinal stromal tumors
topic Minireviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7596635/
https://www.ncbi.nlm.nih.gov/pubmed/33177793
http://dx.doi.org/10.3748/wjg.v26.i40.6195
work_keys_str_mv AT qianxiaohui prevalencediagnosisandtreatmentofprimaryhepaticgastrointestinalstromaltumors
AT yanyingcai prevalencediagnosisandtreatmentofprimaryhepaticgastrointestinalstromaltumors
AT gaobingqiang prevalencediagnosisandtreatmentofprimaryhepaticgastrointestinalstromaltumors
AT wangweilin prevalencediagnosisandtreatmentofprimaryhepaticgastrointestinalstromaltumors